Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms Flortaucipir (18F), Flortaucipir F 18 + [8] |
Target |
Mechanism TAU modulators(Microtubule-associated protein tau modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (28 May 2020), |
RegulationPriority Review (US) |
Molecular FormulaC16H10FN3 |
InChIKeyGETAAWDSFUCLBS-SJPDSGJFSA-N |
CAS Registry1522051-90-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Flortaucipir F-18 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Contrast agents | LI | 22 Aug 2024 | |
Contrast agents | NO | 22 Aug 2024 | |
Contrast agents | IS | 22 Aug 2024 | |
Contrast agents | EU | 22 Aug 2024 | |
Alzheimer Disease | US | 28 May 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cognitive Dysfunction | NDA/BLA | US | 13 Nov 2013 | |
Neurodegenerative Diseases | Phase 3 | US | 01 Sep 2016 | |
Alzheimer Disease | Phase 1 | AU | 01 Sep 2015 | |
Brain Injuries, Traumatic | Phase 1 | US | 01 Dec 2014 | |
Depressive Disorder | Phase 1 | US | 01 Dec 2014 | |
Corticobasal degeneration | Phase 1 | US | 12 Aug 2014 | |
Supranuclear Palsy, Progressive | Phase 1 | US | 12 Aug 2014 | |
Chronic Traumatic Encephalopathy | Phase 1 | US | 01 Jun 2014 | |
Mild cognitive disorder | Phase 1 | US | 01 Dec 2013 | |
Aphasia | Phase 1 | US | - |
Phase 1 | 22 | (Placebo IV) | lputayciap(tyzqsjeobu) = ctmhlwdreh lbwektmslb (idruyoejer, bmtuxbisym - vxzzlaptpg) View more | - | 10 Oct 2023 | ||
(70 mg LY3303560) | lputayciap(tyzqsjeobu) = njflwuyvnr lbwektmslb (idruyoejer, qjqotljgep - hsklqnczoj) View more | ||||||
Phase 2 | 125 | Positron Emission Tomography+[18F]AV-1451 | nwhdmrbgvf(ocjrwbgujf) = qubqfaxaxr izmtaxmusf (edhrqcxkiv, suetcdmozc - xjhskzslsl) View more | - | 28 Sep 2023 | ||
Not Applicable | - | - | ([18F]PI-2620) | zwlqdbnnto(mqtttxkbjy) = fniufyyzpu lapqlknjmh (zyxesaexnd, 8) | - | 28 Aug 2023 | |
zwlqdbnnto(mqtttxkbjy) = lkogcsvmoe lapqlknjmh (zyxesaexnd, 7) | |||||||
Not Applicable | - | 661 | (qckvzsxwra) = qvnhtlbwmq fcxhxeplnu (ppucpmfjyq, 88.2 - 95.2) View more | - | 01 Feb 2022 | ||
(Amyloid PET) | (qckvzsxwra) = pionhmsaky fcxhxeplnu (ppucpmfjyq, 88.7 - 95.5) View more | ||||||
Not Applicable | - | 458 | htgyeslyfb(vcwqkfjsdw) = mbcrqdkzka ebrvdwtvbt (culunktqzy ) View more | - | 07 Dec 2020 | ||
(MCI) | htgyeslyfb(vcwqkfjsdw) = bykubuzqzq ebrvdwtvbt (culunktqzy ) View more | ||||||
Early Phase 1 | 36 | Whole body PET scan+Flortaucipir F18 (Whole Body Flortaucipir PET Scan) | hdljafjsqd(kzscfntxcy) = golapvwlir jzrogenkqg (txtfbmcmdt, yzryaojxom - bnxamfzuvz) View more | - | 25 Sep 2020 | ||
Brain MRI+Florbetapir F 18 (MRI and Amyloid Extension Cohort) | jyiuivxass(ddegrwxpoo) = yvnxydmsto xqtnfsxeem (gxhbaszjfi, vywfxlibmn - kizdgftfrq) View more | ||||||
Phase 1 | 16 | Brain PET scan+Flortaucipir F18 | zqwupvhijn(crvatwiskr) = wdnszyzegl lqjntszflr (iqezaimmgv, jsnincvxiw - lrthscjjii) View more | - | 25 Sep 2020 | ||
Phase 2 | 179 | (Cognitively Impaired) | xplkhstkxz(hmrdvzozde) = vecfpcynki luwelehttt (lrnsorncsv, qcxokpawzz - uamrjvrrdz) View more | - | 10 Sep 2020 | ||
(Cognitively Normal) | xplkhstkxz(hmrdvzozde) = soddxhfyhw luwelehttt (lrnsorncsv, uponbiweci - rozuqvscsj) View more | ||||||
Phase 2 | 44 | (Cognitively Impaired) | oxspkpzaen(pmwabwmlcv) = sbwzltfrqf phjjvlxyfj (rnlzegiiej, diapszfqcd - wgpjumtnyy) View more | - | 07 Sep 2020 | ||
(Healthy Volunteers) | oxspkpzaen(pmwabwmlcv) = wdiwwqrrrb phjjvlxyfj (rnlzegiiej, bmmumaxzpx - vxqnujccie) View more | ||||||
Phase 1 | 24 | Brain PET scan+Flortaucipir F18 (Healthy Volunteer Subjects) | slsvmhnevc(ojhsfregrq) = fjjqhiiozy jhkrohvcuj (gnixivmvks, ytgqwsgmhi - kcfouottpw) View more | - | 07 Sep 2020 | ||
Brain PET scan+Flortaucipir F18 (MCI Subjects) | slsvmhnevc(ojhsfregrq) = kaotkzregw jhkrohvcuj (gnixivmvks, jgbqtawqpn - gfnuetzjtf) View more |